<!DOCTYPE html>
<html lang="en">
<head>
<?php $id='1224-1895'; include '../../seo.php';?>
<?php include '../../side-nav.php';?>
<div class="page-content">
<!--section-->
<div class="section mt-0">
<div class="breadcrumbs-wrap">
<div class="container">
<div class="breadcrumbs">
<a href="https://sprintdiagnostics.in/">Home</a>
<a href="https://www.sprintdiagnostics.in/hyderabad/test/">Test</a>
<span>PML/RARA t(15:17) Qualitative - PCR: A Diagnostic Test for Genetic Abnormality</span>
</div>
</div>
</div>
</div>
<!--//section-->
<!--section-->
<div class="section page-content-first">
<div class="container mt-6">
<div class="row">
<div class="col-md-8 col-lg-8 mt-0 mt-md-0 mb-4">
<h1 class="test-h1">PML/RARA t(15:17) Qualitative - PCR: A Diagnostic Test for Genetic Abnormality</h1>
<div class="post-text">
<p>The PML/RARA t(15:17) Qualitative - PCR test is a diagnostic tool used to detect a specific genetic abnormality associated with a type of leukemia called acute promyelocytic leukemia (APL). This genetic abnormality involves a translocation between chromosomes 15 and 17, resulting in the fusion of two genes: PML (promyelocytic leukemia) and RARA (retinoic acid receptor alpha). The PML/RARA fusion gene is considered a hallmark of APL and plays a critical role in its development.</p>
<p>The PML/RARA t(15:17) Qualitative - PCR test utilizes a technique called polymerase chain reaction (PCR) to detect the presence of the PML/RARA fusion gene in the DNA extracted from blood or bone marrow samples. By identifying this genetic abnormality, the test aids in confirming the diagnosis of APL and guiding appropriate treatment decisions.</p>


<div class="table-wrap">
<table class="table table-striped">
	<thead>
		<tr>
			<th scope="col">Test Name</th>
			<td scope="col">PML/RARA t(15:17) Qualitative - PCR: A Diagnostic Test for Genetic Abnormality</td>
		</tr>
	</thead>
	<tbody>
		<tr>
			<th scope="row">Sample Type</th>
			<td>Blood or Bone Marrow</td>
		</tr>
		<tr>
			<th scope="row">Preparations Required</th>
			<td>No specific instructions are required for this test.</td>
		</tr>
		<tr>
			<th scope="row">Report Time</th>
			<td>24 hours</td>
		</tr>
		<tr>
			<th scope="row">Price in Hyderabad</th>
			<td>â‚¹ 5000</td>
		</tr>
	</tbody>
</table>
</div>
<div class="post-text">
<h2 class="test-h2 mt-3">What is the importance of getting the PML/RARA t(15:17) Qualitative - PCR test done?</h2>
<p>The PML/RARA t(15:17) Qualitative - PCR test is crucial in diagnosing acute promyelocytic leukemia (APL). It helps
    confirm the presence of the PML/RARA fusion gene, which is a characteristic genetic abnormality in APL. This
    information is essential for accurate diagnosis, determining the prognosis, and guiding appropriate treatment
    strategies.</p>
<h2 class="test-h2 mt-3">Is fasting required or any specific preparation needed before the test?</h2>
<p>No specific fasting or preparation is required for the PML/RARA t(15:17) Qualitative - PCR test. You can follow your
    regular eating and drinking habits before the test.</p>
<!--section achieved-->
<?php include "../../include/iconsbox.php" ?>
<!--//section achieved-->

<h2 class="test-h2 mt-3">When should I get this test?</h2>
<p>The PML/RARA t(15:17) Qualitative - PCR test is typically ordered by your healthcare provider if there is a suspicion
    of acute promyelocytic leukemia (APL) based on your symptoms, physical examination, and other laboratory findings.
    The test is performed as part of the diagnostic workup to confirm the presence of the PML/RARA fusion gene.</p>
<h2 class="test-h2 mt-3">What information does the test provide or measure?</h2>
<p>The PML/RARA t(15:17) Qualitative - PCR test detects the presence of the PML/RARA fusion gene in your blood or bone
    marrow sample. Its main purpose is to confirm the diagnosis of acute promyelocytic leukemia (APL) by identifying
    this specific genetic abnormality.</p>
<h2 class="test-h2 mt-3">How often should I be tested for the PML/RARA t(15:17) fusion gene?</h2>
<p>Once the PML/RARA fusion gene is detected and a diagnosis of acute promyelocytic leukemia (APL) is established,
    further testing for this genetic abnormality may not be necessary. However, your healthcare provider will determine
    the appropriate monitoring and follow-up schedule based on your specific treatment plan and individual
    circumstances.</p>
<h2 class="test-h2 mt-3">What are the normal values or results of the PML/RARA t(15:17) Qualitative - PCR test?</h2>
<p>In the context of the PML/RARA t(15:17) Qualitative - PCR test, a positive result indicates the presence of the
    PML/RARA fusion gene, confirming the diagnosis of acute promyelocytic leukemia (APL). A negative result suggests the
    absence of the fusion gene.</p>
<h2 class="test-h2 mt-3">Are there any precautions I should take before or after the test?</h2>
<p>No specific precautions are required before or after the PML/RARA t(15:17) Qualitative - PCR test. However, it is
    always advisable to follow any instructions provided by your healthcare provider regarding medications, lifestyle
    modifications, or other relevant aspects of your care.</p>
<h2 class="test-h2 mt-3">What factors can affect the levels of the PML/RARA fusion gene?</h2>
<p>The levels of the PML/RARA fusion gene are primarily influenced by the presence or absence of acute promyelocytic
    leukemia (APL). In individuals with APL, the fusion gene is expected to be present. However, factors such as disease
    progression, response to treatment, and minimal residual disease can impact the levels of the fusion gene. Regular
    monitoring of the PML/RARA fusion gene may be recommended to assess treatment response and disease progression.</p>
<h2 class="test-h2 mt-3">Which doctor should I consult if my test results show an abnormal value?</h2>
<p>If your test results indicate the presence of the PML/RARA fusion gene, it is important to consult with a
    hematologist or an oncologist specializing in the treatment of leukemia, particularly acute promyelocytic leukemia
    (APL). These specialists have expertise in managing hematological malignancies and can provide you with appropriate
    guidance and treatment options based on your specific condition.</p>
<h2 class="test-h2 mt-3">Can the PML/RARA t(15:17) Qualitative - PCR test be done at home?</h2>
<p>No, the PML/RARA t(15:17) Qualitative - PCR test cannot be performed at home. It requires specialized laboratory
    equipment and expertise to accurately detect the PML/RARA fusion gene. The test must be conducted in a clinical
    laboratory under controlled conditions to ensure accurate and reliable results.</p>
<h2 class="test-h2 mt-3">Are there any known side effects or risks associated with the PML/RARA t(15:17) Qualitative -
    PCR test?</h2>
<p>The PML/RARA t(15:17) Qualitative - PCR test is a relatively safe diagnostic procedure that involves analyzing a
    sample of your blood or bone marrow. The risks associated with the test are minimal and mainly related to the
    collection of the sample, which may cause slight discomfort, bruising, or bleeding at the site of the needle
    insertion. These risks are generally rare and temporary.</p>
<h2 class="test-h2 mt-3">Is the PML/RARA t(15:17) Qualitative - PCR test covered by insurance?</h2>
<p>The coverage of the PML/RARA t(15:17) Qualitative - PCR test by insurance providers can vary. It is advisable to
    check with your specific insurance company to understand the extent of coverage for this particular test. Your
    healthcare provider can also assist you in determining insurance coverage and provide any necessary documentation or
    justification for the test.</p>
<h2 class="test-h2 mt-3">What are the treatment options for acute promyelocytic leukemia (APL)?</h2>
<p>The treatment of acute promyelocytic leukemia (APL) typically involves a combination of chemotherapy and targeted
    therapy. All-trans retinoic acid (ATRA) and arsenic trioxide are commonly used drugs that specifically target the
    PML/RARA fusion protein, aiming to induce remission and prevent the proliferation of leukemic cells. In some cases,
    additional chemotherapy drugs may be prescribed to further eliminate cancer cells. Treatment plans are
    individualized based on the patient's specific condition, overall health, and risk factors.</p>
<h2 class="test-h2 mt-3">What are the potential complications of acute promyelocytic leukemia (APL)?</h2>
<p>If left untreated or not properly managed, acute promyelocytic leukemia (APL) can lead to several complications.
    These may include bleeding disorders due to low platelet count, infections due to compromised immune function, organ
    damage or failure, and coagulopathy (blood clotting disorders). Prompt diagnosis and appropriate treatment are
    crucial to minimize the risk of complications and improve overall outcomes.</p>
<h2 class="test-h2 mt-3">Can the PML/RARA t(15:17) Qualitative - PCR test detect minimal residual disease (MRD)?</h2>
<p>Yes, the PML/RARA t(15:17) Qualitative - PCR test can be used to detect minimal residual disease (MRD) in patients
    with acute promyelocytic leukemia (APL). MRD refers to the presence of small amounts of leukemic cells that may
    remain after treatment. Monitoring MRD levels helps assess treatment response and guide further therapy decisions,
    such as the duration of treatment or the need for consolidation therapy.</p>
<h2 class="test-h2 mt-3">How often should the PML/RARA t(15:17) Qualitative - PCR test be done?</h2>
<p>The frequency of PML/RARA t(15:17) Qualitative - PCR testing depends on various factors, including the stage of the
    disease, response to treatment, and individual patient characteristics. Initially, the test may be performed at the
    time of diagnosis to confirm the presence of the PML/RARA fusion gene. Subsequent testing is typically done at
    regular intervals to monitor treatment response, detect minimal residual disease (MRD), and assess disease
    progression. Your healthcare provider will determine the appropriate testing schedule for your specific case.</p>
<h2 class="test-h2 mt-3">Is the PML/RARA t(15:17) Qualitative - PCR test only used for diagnosing acute promyelocytic
    leukemia (APL)?</h2>
<p>The PML/RARA t(15:17) Qualitative - PCR test is primarily used for diagnosing acute promyelocytic leukemia (APL) due
    to its characteristic genetic abnormality. However, in some cases, this test may also be used for monitoring disease
    response and detecting minimal residual disease (MRD) in individuals with APL. It is important to discuss the
    specific indications for the test with your healthcare provider.</p>
 

</div>		
</div>			
</div>
<!--form section-->
<?php include "../../include/bookslot.php" ?>
<!--form section-->
</div>
</div>
<!--//section-->
</div>
</div>
<?php include '../../footer.php';?>
</body>
</html>